Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful vigilantly but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past several shares of mine. The first CytoDyn article of mine, “CytoDyn: What to be able to Do When It is Too Good to be able to Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire employment interview that I came away with a bad impression of the business.

Irony of irony, my bad opinion of the company has grown steadily, though the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the know-how as well as linked intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) along with the very first brand new drug application endorsement ($5 million), and also royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and numerous therapies, it has this single therapy as well as a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an active organization with diverse interests albeit centered on leronlimab, several disease sorts, multiple delivering presentations in addition to multiple publications.

Might all of it be smoke and mirrors? That’s a question I have been asking myself from the really beginning of my interest in this particular company. Judging by the multiples of thousands of various responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this particular question.

CytoDyn is a traditional battleground, or even some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *